Revealing Program Updates from LY3537982, a Highly Selective & Potent KRAS G12C Inhibitor

Time: 9:30 am
day: Conference Day Two


  • Discussing the discovery and rational design of LY3537982 its transition from bench to clinic
  • Reviewing recent first-in-human data for LY3537982 in patients with KRAS G12C-Mutant Advanced Solid Tumors, Including NSCLC and CRC
  • Exploring LY3537982 development avenues and promising future directions